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Background: Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment
outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs.
Methods: We conducted a retrospective cohort study of postmenopausal women with breast cancer on AIs who had
completed a survey about their symptom experience on AIs with specific measurements of joint pain. The primary
outcome was premature discontinuation of AIs, defined as stopping the medication prior to the end of prescribed
therapy. Multivariate Cox regression modeling was used to identify predictors of premature discontinuation.
Results: Among 437 patients who met eligibility criteria, 47 (11%) prematurely discontinued AIs an average of 29
months after initiation of therapy. In multivariate analyses, patient-reported worst joint pain score of 4 or greater on the
Brief Pain Inventory (BPI) (Hazard Ratio [HR] 2.09, 95% Confidence Interval [CI] 1.14-3.80, P = 0.016) and prior use of
tamoxifen (HR 2.01, 95% CI 1.09-3.70, P = 0.026) were significant predictors of premature discontinuation of AIs. The
most common reason for premature discontinuation was joint pain (57%) followed by other therapy-related side effects
(30%). While providers documented joint pain in charts for 82% of patients with clinically important pain, no quantitative
pain assessments were noted, and only 43% provided any plan for pain evaluation or management.
Conclusion: Worst joint pain of 4 or greater on the BPI predicts premature discontinuation of AI therapy. Clinicians
should monitor pain severity with quantitative assessments and provide timely management to promote optimal
adherence to AIs.
Keywords: Aromatase inhibitor, Joint pain, Adherence, Adverse effects, Musculoskeletal, Breast cancer, Pain diagnosis,
Pain management, SurvivorshipBackground
Third-generation aromatase inhibitors (AIs) are commonly
prescribed as standard adjuvant therapy for postmeno-
pausal breast cancer survivors with hormone-receptor
positive disease and are associated with improved disease-
free survival compared with the previous standard of tam-
oxifen therapy [1-4]. The recommended duration of initial
adjuvant endocrine therapy is five years though some* Correspondence: jun.mao@uphs.upenn.edu
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reproduction in any medium, provided the orpatients have benefitted from extended therapy. Current
American Society of Clinical Oncology guidelines recom-
mend incorporating an AI either as primary, sequential
(following 2–3 years of tamoxifen), or extended therapy
(following 5 years of tamoxifen) [5].
Despite the survival benefits of AIs, many women
demonstrate some degree of non-adherence with their
use. Non-adherence, a term which comprises both non-
compliance with dosing, timing, and instruction of medi-
cation and non-persistence, or early discontinuation of
medication, represents an emergent area to intervene for
treatment benefit. Indeed, non-adherence of adjuvant
endocrine therapy has been associated with increased
mortality in breast cancer patients [6]. In the emergingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from 13-35% [7-9].
Despite the prevalence of early medication discontinu-
ation and its deleterious effects, little is understood
about risk factors for premature discontinuation of AI
therapy. The available adherence research largely con-
sists of medical claims-based epidemiological studies in
which younger age, increased cormorbidities, and higher
medication co-payments have been noted as risk factors
for nonadherence to adjuvant therapy [10-12]. While
these studies are useful in quantifying the magnitude of
medication nonadherence, they often lack clinical in-
sights into patient perspectives such as the reasons for
premature discontinuation. AI-associated arthralgia, or
joint pain, has been recognized as a particularly debili-
tating side effect which develops in nearly half of women
treated with AIs [13,14]. In online breast cancer message
board discussions, joint pain is the most commonly
mentioned side effect of AIs and often leads to AI dis-
continuation [15]. Although joint pain was the most
cited reason for premature discontinuation of AIs in a
recently published clinical trial, little is known about
how levels of joint pain may predict early discontinu-
ation of therapy [9]. Appropriate identification of pa-
tients most at risk for discontinuing therapy may
provide an opportunity for early interventions to allevi-
ate the adverse effects of joint pain and improve medica-
tion adherence. We conducted a retrospective cohort
study to determine whether patient-reported joint pain
severity predicts premature discontinuation of AIs. As a
secondary aim, we examined provider-documented pain
and practice behaviors among those with clinically im-
portant pain.
Methods
Study design and patient population
Participants were identified from the Wellness after
Breast Cancer (WABC) study, an ongoing cohort study
of breast cancer patients who completed a survey at the
time of recruitment between March 2008 and July 2009 at
the University of Pennsylvania (Philadelphia, PA, USA)
[16]. The inclusion criteria for the WABC study were: (1)
postmenopausal status (amenorrhea ≥ 12 months), (2)
histologically-confirmed stage I-III hormone receptor-
positive breast cancer, (3) exposure to a third-generation
AI (anastrozole, letrozole, or exemestane), (4) completion
of all chemotherapy and/or radiotherapy at least one
month prior to survey date, (5) approval of the patient’s
primary oncologist, and (6) ability to provide informed
consent. Participants had been on AI therapy on average
26.7 months at time of entry to the WABC cohort.
Participants were approached while in the waiting
room for their oncology appointments by trained re-
search assistants. After informed consent was obtained,each participant completed a self-administered survey.
We performed a retrospective cohort study from October
- December 2011 of all women enrolled in the WABC
study who were taking an AI at the time of survey as de-
termined by chart review. Detailed chart abstraction was
performed to measure study related outcomes and vari-
ables. The study was approved by the Institutional Re-
view Board of the University of Pennsylvania.
Primary outcome: premature discontinuation
Premature discontinuation of AIs, defined as stopping
medication prior to the end of prescribed therapy, was
determined by chart review of outpatient electronic
medical records (EMR). Medication events were evalu-
ated from the survey date to December 2011 (follow-up
period of 29–45 months). Each oncology visit progress
note was reviewed for information concerning the pre-
scribed AI and planned duration of therapy at the time
of prescription. Patients varied in their duration of ther-
apy depending on whether an AI was incorporated as
primary, sequential, or extended adjuvant endocrine
therapy and we deferred to the provider-determined end
date for all patients as documented in the EMR [5]. AI
switches and drug holidays were not regarded as prema-
ture discontinuation events unless the patient ultimately
discontinued their second AI or did not resume AI ther-
apy after a drug holiday. For those who stopped therapy
early, the reasons for premature discontinuation were
abstracted from the EMR on the date of the clinical visit.
We regarded premature discontinuation as an intentional
action of the patient in line with the definition of non-
persistence presented by Guth et al. [17]. Discontinuations
of therapy due to breast cancer recurrence were not consid-
ered premature discontinuation events. We censored sub-
jects at the time of disease recurrence (N=5), death (N=8),
or loss to follow up from the outpatient clinic (N=20).
Patient-reported joint pain
Patient-reported pain outcomes were obtained from the
one time baseline survey that established the cohort. To
evaluate clinically important joint pain, we used the
worst pain measure from the Brief Pain Inventory (BPI)
with slight modifications [18]. Participants were asked to
rate their worst joint pain in the past 24 hours on a scale
of 0 (no pain) to 10 (pain as bad as you can imagine).
We a priori dichotomized patients into two groups:
those reporting joint pain severity from 0–3 and those
reporting joint pain from 4–10, a level at which pain be-
comes clinically important and interferes with daily
functioning [19]. To evaluate the presence of AI-related
arthralgia (AIAA), women were first asked if they were
experiencing joint pain. They were then asked to spe-
cify the perceived source of their arthralgia: “prior
osteoarthritis; aromatase inhibitors; aging; weight gain;
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don’t have joint symptoms.” Respondents were able to
choose more than 1 option. Consistent with our prior
research, patients who selected “aromatase inhibitors”
were considered to have AIAA [14].
Covariates
Self-reported demographic variables included age, race/
ethnicity, education level, date of last menstrual period
(LMP), and reasons for menopause (natural or induced).
Comorbidities were assessed using a standard checklist
and categorized into 0, 1, or 2, or more conditions. Clin-
ical variables such as tumor type, stage, treatment regi-
men, and treatment status were collected via medical
chart abstraction.
Secondary outcome: clinician documentation of joint pain
Provider encounter notes in the EMR on the date each
subject completed the initial WABC survey were reviewed
to compare provider and patient reports of joint pain. We
analyzed the visit note for documentation of joint pain
and, if present, indications of the level of joint pain using
quantitative pain ratings and whether a plan to address
joint pain was provided.
Statistical analysis
Data analysis was conducted using STATA 12 for Windows
(STATA Corporation, College Station, TX). Survival ana-
lyses were performed using the Kaplan-Meier method to
examine individual predictors of premature discontinuation
from the time of initial survey. Multivariate Cox propor-
tional hazards regression models were used to estimate the
association between predictive variables (those variables
that were associated with the outcome in bivariate analysesFigure 1 Patient selection and follow up.with P <0.10) and premature AI discontinuation. All statis-
tics were two-sided with P <0.05 indicating significance.
Results
Patient characteristics
Of 501 subjects enrolled in the WABC study, 461 (92%)
were taking an AI at survey date. Twenty-four subjects
(4.8%) were excluded after chart review revealed meta-
static disease at the time of enrollment, leaving a total of
437 eligible patients (Figure 1). Among these subjects
(Table 1), the mean age was 62 years (standard deviation
10.2). Although the majority of patients (82%) was non-
Hispanic white, a substantial proportion (15%) was non-
Hispanic black. In the analysis, we combined the race
categories into white and nonwhite. More than three-
quarters of participants had a college education or greater
(343 subjects, 79%) with 21% reporting high school or less.
Regarding prior treatment, 268 (61%) had undergone
chemotherapy (see Table 1 for taxane vs. non-taxane regi-
mens) and 147 (34%) reported prior use of tamoxifen. The
majority of patients (81%) reported taking anastrozole. A
third of subjects (156; 36%) met criteria for clinically im-
portant pain with worst joint pain rating between 4–10 in
the past 24 hours and nearly half of all subjects (206; 47%)
reported joint symptoms attributable to AIs (Table 1).
Premature discontinuation
Among the cohort, 192 (44%) had completed their course
of AI therapy for the full duration prescribed, while 193
(44%) continued to take an AI. Forty-seven women (11%)
prematurely discontinued their course of AI therapy after
an average of 29.4 ± 18.2 months (Figure 1). The most
common reason for premature discontinuation recorded
by providers in the EMR was joint pain (57%) followed by
other therapy-related side effects (30%) and non-therapy-
Table 1 Characteristics of study participants
N % HR (95% CI) P-value
Total (N, %) 437 100.0
Age, years 0.26
>65 138 31.6 1
55-65 201 46.0 0.58 (0.30-1.13)
<55 98 22.4 0.81 (0.39-1.68)
Race 0.51
White 360 82.4 1
Non-white 77 17.6 0.77 (0.34-1.72)
Education 0.071
College or above 343 78.7 1
High school or less 93 21.3 0.42 (0.17-1.08)
Years since LMP 0.59
>10 242 56.1 1
5-10 108 25.1 1.42 (0.72-2.77)
<5 81 18.8 1.05 (0.48-2.29)
Reasons for menopause
Natural 226 52.4 1
Induced 205 47.6 1.44 (0.81-2.56)
Comorbid conditions 0.35
None 68 15.6 1
One 133 30.4 0.84 (0.38-1.89)
Two or more 236 54.0 0.59 (0.27-1.30)
Stage 0.46
I 169 38.6 1
II 214 49.0 0.77 (0.42-1.41)
III 54 12.4 0.56 (0.19-1.63)
Chemotherapy 0.92
None 169 38.7 1
Chemotherapy but no
taxane
104 23.8 0.92 (0.41-2.05)
Chemotherapy included
taxane
164 37.5 1.08 (0.57-2.04)
Years since start of AI 0.66
<1 139 31.8 1
1-3 145 33.2 0.74 (0.39-1.43)
>3 153 35.0 0.81 (0.38-1.76)
Prior tamoxifen use 0.088
No 290 66.4 1
Yes 147 33.6 1.70 (0.94-3.08)
Aromatase inhibitor 0.22
Anastrozole 299 70.1 1
Letrozole 80 18.7 0.57 (0.25-1.30)
Exemestane 47 11.0 0.98 (0.37-2.56)
0.037
Table 1 Characteristics of study participants (Continued)
Patient-reported worst
joint pain
0-3 277 64.0 1
4-10 156 36.0 1.86 (1.04-3.31)
Patient-reported joint
pain related to AIs
0.14
No 231 52.9 1
Yes 206 47.1 1.55 (0.87-2.76)
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, LMP last
menstrual period, AI aromatase inhibitor.
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AI therapy due to breast cancer recurrence.
Predictors of premature discontinuation
In univariate analyses, patient-reported joint pain sever-
ity ≥4 (measured at cohort entry) was significantly asso-
ciated with premature discontinuation of AI therapy
(P = 0.037). Higher education level (P = 0.071) and prior
use of tamoxifen (P = 0.088) were also associated with
early discontinuation but did not reach statistical signifi-
cance (Table 1). In the multivariate regression model,
adjusting for variables selected from the univariate ana-
lyses, joint pain severity and prior use of tamoxifen were
statistically significant independent predictors of prema-
ture discontinuation (Table 2). Women reporting joint
pain severity of 4 or greater were more likely to stop AI
therapy early than women reporting joint pain of 3 or less
(Hazard Ratio [HR] 2.09, 95% Confidence Interval [CI]
1.14-3.80, P = 0.016) (Figure 2). Prior tamoxifen use was
also significantly associated with premature discontinuation
of AI therapy (HR 2.01, 95% CI 1.09-3.70, P = 0.026).
Clinician documentation of joint pain
We restricted our analysis of provider behavior to include
only individuals reporting clinically important pain (worst
joint pain rating 4–10) on the initial survey (N = 151).
Provider (e.g., MD or NP) documentation of joint pain
was noted in 124 visits (82%), however, no quantitative as-
sessments of pain were observed. Providers documented a
plan for joint pain (e.g., imaging, specialist referral, return
if pain worsens) in 43% of visits.
Discussion
In this retrospective analysis we evaluated whether patient-
reported joint pain severity is predictive of premature dis-
continuation of AIs. After controlling for demographic and
clinical characteristics, patients who reported worst joint
pain severity of 4 or greater on the BPI were significantly
more likely to prematurely discontinue AI therapy. How-
ever, patient-reported AIAA did not predict premature dis-
continuation. Although clinicians often documented the
Table 2 Predictors of premature discontinuation of aromatase inhibitors
Univariate analyses Multivariate analysis
Predictors HR 95% CI P-value HR 95% CI P-value
Patient-reported worst joint pain
0-3 1 1
4-10 1.86 1.04-3.31 0.037 2.09 1.14-3.80 0.016
Prior tamoxifen use
No 1 1
Yes 1.7 0.94-3.07 0.088 2.01 1.09-3.70 0.026
Education
College and above 1 1
High school or less 0.42 0.17-1.08 0.071 0.37 0.13-1.03 0.057
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval.
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ally important pain, no quantitative assessment was used,
and only half offered a plan to further evaluate or treat
pain. These findings warrant future clinical improvements
in both pain diagnosis and management for breast cancer
survivors receiving AI therapy.
Premature discontinuation specific to AI therapy has
been reported to range from 13-35% in the emerging lit-
erature [7-9]. These variations may be due to population
characteristics (clinical trial vs. community), time to
follow-up, and different definitions of premature discon-
tinuation. In our study 11% of women who were on AI
therapy at cohort entry stopped medication during a
follow-up period of 29–45 months. This rate is predict-
ably lower than the total premature discontinuation rate
of the entire cohort given that nearly half of our study
population was still taking an AI at the time of the study
and remain at risk for prematurely discontinuing therapy.
Additionally, 40 individuals were excluded from analysisFigure 2 Kaplan-Meier curve comparing continuation of AI therapy b
Inventory of 0-3 with those reporting worst pain of 4-10 (clinically imfor not taking AIs at the time of recruitment. Among
those, 29 patients had prematurely discontinued AI ther-
apy; in sum, 16% of the sample which falls in the range of
reported premature discontinuation rates in the literature.
Premature discontinuation, as one aspect of non-
adherence, has substantial negative effects by the very
meaning of its definition – the complete cessation of
therapy. Hershman et al. demonstrated an absolute
increase in mortality of more than 7% in women who
prematurely discontinued hormonal therapy with either
an AI or tamoxifen compared to those who continued
therapy over a 4.5 year period. Even with adjustment for
relevant clinical and demographic variables, early dis-
continuation was associated with a relative 26% increase
in all-cause mortality [6]. These results emphasize the
importance of identifying patients most at risk for stop-
ping AIs and targeting interventions toward this group.
We found patient-reported worst joint pain severity of 4
or greater to be predictive of premature AI discontinuation.etween patients reporting worst joint pain score on Brief Pain
portant pain).
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not a significant predictor, suggesting that it is the severity
of joint pain, rather than its assumed origins, that may
lead women to stop therapy. The finding of joint pain se-
verity as a predictor of premature discontinuation is con-
sistent with a recently published study in a clinical trial
setting in which higher baseline pain is a positive predictor
of early discontinuation of AI therapy [9]. These findings
suggest that although patients may function reasonably
well at low pain levels, a threshold may exist beyond
which pain is difficult to ignore and may impact adher-
ence behavior. Our results suggest a BPI worst pain rating
of 4 or greater may be a threshold for predicting prema-
ture discontinuation to AI therapy, a finding warranting
validation in independent datasets.
In contrast to research suggesting physicians' failure to
routinely assess patient pain [20], it is encouraging that
joint pain was documented in the majority of provider
notes for patients reporting pain ratings of 4 or greater.
Despite the high percentage of symptom reporting, the
lack of specific pain quantification warrants improvement.
Quantitative pain assessments provide a reliable and valid
measure of pain intensity and are recommended by
the National Comprehensive Cancer Network (NCCN)
Practice Guidelines for cancer pain [21]. A simple meas-
ure such as a 10-point numerical rating scale of pain can
be easily and reliably incorporated into an outpatient visit
[20]. With the emergence of health technology, electronic
patient-report assessments can be utilized to provide
quantitative assessments of patient pain and facilitate
patient-provider communication regarding symptom dis-
tress [22]. Ultimately, with targeted therapies currently
under investigation to alleviate joint pain related to AIs
[23-25], patients and their providers will have increasingly
effective options to manage joint pain rather than discon-
tinuing AI therapy.
In multivariate modeling, we found that controlling for
joint pain severity strengthened the association between
prior tamoxifen use and premature discontinuation of
AIs. This suggests that for patients who experience the
same level of pain severity, they are more likely to discon-
tinue AIs if they had prior use of tamoxifen. Based on clin-
ical experience, it is possible that prior tamoxifen users
who perceived that they had adequate hormonal therapy
were therefore less tolerant of side effects of AIs. Another
possible explanation is that prior tamoxifen users have
gotten used to the side effects of tamoxifen over time and
when they experience new side effects related to AIs, they
prefer to switch back to tamoxifen rather than staying
on AIs.
Our study has several potential limitations. First, in our
retrospective cohort study design, we assessed joint pain
one time to predict premature discontinuation of AIs. As
pain may change over time, our data does not provide anabsolute cut-off pain level necessary to discontinue AIs
and requires validation in independent datasets. Addition-
ally, our retrospective design did not include patients who
prematurely discontinued AIs prior to enrollment which
may bias our results towards null. Thus, the strength of
association between joint pain severity and premature dis-
continuation may in fact be even stronger. Third, our out-
come focused on premature discontinuation based on
chart-abstraction. Theoretically, patients may discontinue
therapy without informing their providers; however, if that
is the case, it should bias our results towards null. Lastly,
our research was conducted in a large academic medical
center which may limit the ability to generalize findings to
community hospital settings.
Conclusions
Despite these limitations, our study had a number of
strengths including a large clinical population, incorpor-
ation of patient-reported outcome, and examination of
provider pain diagnosis and management behaviors. We
found that patient-reported joint pain severity of 4 or
greater was significantly associated with early discontinu-
ation of therapy. These results highlight the importance of
medical providers performing quantitative assessments of
pain and inquiring about other medication adverse effects
in order to appropriately identify patients who may be at
risk for stopping therapy. Targeting interventions for these
patients will ultimately optimize adherence to AIs and
improve both quality of life and survival outcomes for
women with breast cancer.
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